Home Stock

Stock Research: 10x Genomics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

10x Genomics

NSQ:TXG US88025U1097
52
  • Value
    48
  • Growth
    75
  • Safety
    Safety
    25
  • Combined
    52
  • Sentiment
    51
  • 360° View
    360° View
    52
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

10x Genomics, Inc. is a life science technology company providing integrated solutions for single cell and spatial biology. Its main businesses include instruments, consumables, and software for Chromium and Visium platforms, supporting single cell gene expression, immune profiling, ATAC, and spatial gene expression. The company operates globally. In the last fiscal year, the company had a market cap of $1,533 million, profits of $415 million, revenue of $611 million, and 1,306 employees.

more

ANALYSIS: With an Obermatt 360° View of 52 (better than 52% compared with alternatives), overall professional sentiment and financial characteristics for the stock 10x Genomics are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for 10x Genomics. The consolidated Growth Rank has a good rank of 75, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 75% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 51, which means that professional investors are more optimistic about the stock than for 51% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 48, which means that the share price of 10x Genomics is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 52% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 25, which means that the company has a financing structure that is riskier than those of 75% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Price vs. Earnings (P/E)
Country USA
Industry Life Sciences Tools & Services
Size Medium
Website 10xgenomics.com
Index
NASDAQ
10x Genomics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 55 12 9
Growth
75 19 59 59
Safety
Safety
25 75 60 54
Sentiment
51 9 79 71
360° View
360° View
52 18 61 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
6 20 39 38
Opinions Change
50 6 50 50
Pro Holdings
n/a 8 65 69
Market Pulse
94 60 89 70
Sentiment
51 9 79 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 55 12 9
Growth
75 19 59 59
Safety Safety
25 75 60 54
Combined
52 44 40 28
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
46 61 11 9
Price vs. Earnings (P/E)
100 12 12 4
Price vs. Book (P/B)
32 53 12 6
Dividend Yield
1 1 1 1
Value
48 55 12 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
12 60 79 82
Profit Growth
45 36 21 91
Capital Growth
81 44 4 7
Stock Returns
89 7 91 33
Growth
75 19 59 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
76 100 100 100
Refinancing
41 63 33 31
Liquidity
6 1 12 7
Safety Safety
25 75 60 54

Similar Stocks

Discover high‑ranked alternatives to 10x Genomics and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews